

and adopt, as well, and we can move forward in such a positive direction for people that you heard about today from my colleagues.

Lives that are on the line can be saved by innovation. The quicker we get that innovation to the market, the more we can reduce costs and save lives.

Mr. Speaker, I call on my colleagues to support passage of this very important lifesaving legislation, and I yield back the balance of my time.

Ms. ESHOO. Mr. Speaker, I rise today in support of H.R. 2430, the FDA Reauthorization Act of 2017 to reauthorize four important user fee programs: the Prescription Drug User Fee Act, the Medical Device User Fee Act, the Generic Drug User Fee Act, and the Biosimilar User Fee Act. These critically important laws have improved patient access to important therapies and expedited the FDA's approval times while upholding the most rigorous standards for patient safety.

The Prescription Drug User Fee Act (PDUFA) was enacted in 1992 when drug review times were lagging and FDA simply couldn't keep up with the flood of new drug applications. Through user fees paid by applicants, PDUFA gave FDA the resources it needed to hire and support more staff. The program has been successful in reducing review-time backlogs and expediting safe and effective therapies to patients.

My legislation created the Medical Device User Fee Act (MDUFA), which was enacted in 2002 and has resulted in significant changes to the medical device industry and within the medical device center at the FDA. Through this user fee program, the device center has improved its efficiency and reduced the time it takes to bring effective medical devices to market. This legislation builds on the progress made in previous user fee agreements and will produce important developments for the medical device industry.

The Generic Drug User Fee Agreement (GDUFA) was enacted in 2012 and takes important steps to bring lower-priced drugs to the market more quickly for the American people. Finally, the Biosimilar User Fee Agreement (BsUFA), which was first enacted in 2012 through legislation I authored, is critical to supporting the nascent biosimilar industry and will lead to meaningful progress, breakthroughs and cures for the American people.

Previous user fee reauthorizations have included significant gains for pediatric populations. Before the Better Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA), which I authored, the vast majority of drugs (more than 80 percent) used in children were used off-label, without data for their safety and efficacy. Today, that number has been reduced to 50 percent because of my legislation. Both programs were permanently reauthorized in 2012, and while this agreement includes important changes to BPCA and PREA, there remains a need for more meaningful improvements. This legislation lays important groundwork and provides the foundation for future progress.

Finally, I urge my colleagues in the Senate to take up this legislation swiftly. It's imperative that both houses of Congress pass this legislation and send it to the President in a timely manner for him to sign into law in order to provide essential resources to the FDA so they can continue to do their critical work.

Ms. MATSUI. Mr. Speaker, I rise today in support of H.R. 2430, the FDA user fee reauthorization bill that I worked on with my colleagues on the Energy & Commerce Committee.

Without Congress' swift action to reauthorize this bill, the FDA would not be able to conduct its critical work ensuring that our nation's drugs and devices are safe and effective.

Patients and families across the country battling diseases like Alzheimer's, cancer, multiple sclerosis (MS), and diabetes, rely on innovation to provide new life-saving and life-enhancing treatments and hopefully one day, cures. Without the FDA, we would not be able to ensure that those treatments and cures work and that they're safe.

To quote Dr. Jeff Allen of the Friends of Cancer Research, "for the people who currently depend on safe and effective medicines . . . for those who are holding strong for breakthroughs to come . . . and for every future patient . . . there isn't time to waste."

I urge my colleagues to support the passage of this bill.

Mrs. MIMI WALTERS of California. Mr. Speaker, I am pleased that the House is considering H.R. 2430, the FDA Reauthorization Act of 2017. I note that H.R. 2430 would provide the U.S. Food and Drug Administration (FDA) with new statutory authority to require the sponsor of an orphan-designated drug, which has certain similarities to an already approved drug, to demonstrate "clinical superiority" compared to the already approved drug as a condition of receiving seven years of market exclusivity.

This authority will limit the number of drugs that are automatically entitled to seven years of exclusivity, while maintaining incentives for the development of innovative treatments for rare diseases.

I also note that the bill would improve transparency of the FDA's execution of the Orphan Drug Act. Specifically, the bill directs the FDA to notify a sponsor in writing of any clinical superiority rationale on which the FDA relied in designating the sponsor's drug as an orphan drug. Further, it would require the FDA to publish its clinical superiority findings summaries for all drugs granted exclusivity based on a demonstration of clinical superiority.

I urge my colleagues to support the FDA Reauthorization Act of 2017.

The SPEAKER pro tempore (Mr. MURPHY of Pennsylvania). The question is on the motion offered by the gentleman from Oregon (Mr. WALDEN) that the House suspend the rules and pass the bill, H.R. 2430, as amended.

The question was taken; and (two-thirds being in the affirmative) the rules were suspended and the bill, as amended, was passed.

A motion to reconsider was laid on the table.

#### ANNOUNCEMENT BY THE SPEAKER PRO TEMPORE

The SPEAKER pro tempore. Pursuant to clause 8 of rule XX, proceedings will resume on questions previously postponed.

Votes will be taken in the following order:

Ordering the previous question on House Resolution 431;

Adopting House Resolution 431, if ordered; and

Suspending the rules and passing H.R. 1492.

The first electronic vote will be conducted as a 15-minute vote. Remaining electronic votes will be conducted as 5-minute votes.

#### PROVIDING FOR CONSIDERATION OF H.R. 2810, NATIONAL DEFENSE AUTHORIZATION ACT FOR FISCAL YEAR 2018, AND PROVIDING FOR CONSIDERATION OF H.R. 23, GAINING RESPONSIBILITY ON WATER ACT OF 2017

The SPEAKER pro tempore. The unfinished business is the vote on ordering the previous question on the resolution (H. Res. 431) providing for consideration of the bill (H.R. 2810) to authorize appropriations for fiscal year 2018 for military activities of the Department of Defense and for military construction, to prescribe military personnel strengths for such fiscal year, and for other purposes, and providing for consideration of the bill (H.R. 23) to provide drought relief in the State of California, and for other purposes, on which the yeas and nays were ordered.

The Clerk read the title of the resolution.

The SPEAKER pro tempore. The question is on ordering the previous question.

The vote was taken by electronic device, and there were—yeas 234, nays 183, not voting 16, as follows:

[Roll No. 347]

YEAS—234

Abraham	Cramer	Harper
Aderholt	Crawford	Harris
Allen	Culberson	Hartzler
Amash	Curbelo (FL)	Hensarling
Amodei	Davidson	Herrera Beutler
Arrington	Davis, Rodney	Hice, Jody B.
Babin	Denham	Higgins (LA)
Bacon	Dent	Hill
Banks (IN)	DeSantis	Holding
Barletta	DesJarlais	Hollingsworth
Barton	Diaz-Balart	Hudson
Bergman	Donovan	Huizenga
Biggs	Duffy	Hultgren
Bilirakis	Duncan (SC)	Hunter
Bishop (MI)	Duncan (TN)	Hurd
Bishop (UT)	Dunn	Issa
Black	Emmer	Jenkins (KS)
Blackburn	Estes (KS)	Jenkins (WV)
Blum	Farenthold	Johnson (LA)
Bost	Faso	Johnson (OH)
Brady (TX)	Ferguson	Jones
Brat	Fitzpatrick	Jordan
Bridenstine	Fleischmann	Joyce (OH)
Brooks (AL)	Flores	Katko
Brooks (IN)	Fortenberry	Kelly (MS)
Buchanan	Foxx	Kelly (PA)
Buck	Franks (AZ)	King (IA)
Budd	Frelinghuysen	King (NY)
Burgess	Gaetz	Kinzinger
Byrne	Gallagher	Knight
Calvert	Garrett	Kustoff (TN)
Carter (GA)	Gianforte	Labrador
Carter (TX)	Gibbs	LaHood
Chabot	Gohmert	LaMalfa
Cheney	Goodlatte	Lamborn
Coffman	Gosar	Lance
Cole	Gowdy	Latta
Collins (GA)	Granger	Lewis (MN)
Collins (NY)	Graves (GA)	LoBiondo
Comer	Graves (LA)	Long
Comstock	Graves (MO)	Loudermilk
Conaway	Griffith	Love
Cook	Grothman	Lucas
Costello (PA)	Handel	Luetkemeyer

NAYS—183

Adams	Frankel (FL)	Moore
Aguilar	Fudge	Moulton
Barragán	Gabbard	Murphy (FL)
Bass	Gallego	Nadler
Beatty	Garamendi	Neal
Bera	Gomez	Nolan
Beyer	Gonzalez (TX)	Norcross
Bishop (GA)	Gottheimer	O'Halleran
Blumenauer	Green, Al	O'Rourke
Blunt Rochester	Green, Gene	Pallone
Bonamici	Grijalva	Panetta
Boyle, Brendan F.	Gutiérrez	Pascarella
Brady (PA)	Hanabusa	Payne
Brown (MD)	Hastings	Perlmutter
Brownley (CA)	Heck	Peters
Bustos	Higgins (NY)	Peterson
Butterfield	Himes	Pingree
Capuano	Hoyer	Pocan
Carbajal	Huffman	Polis
Cárdenas	Jackson Lee	Price (NC)
Carson (IN)	Jayapal	Quigley
Cartwright	Jeffries	Raskin
Castor (FL)	Johnson (GA)	Rice (NY)
Castro (TX)	Johnson, E. B.	Richmond
Chu, Judy	Kaptur	Rosen
Cicilline	Keating	Royal-Allard
Clark (MA)	Kelly (IL)	Ruiz
Clarke (NY)	Kennedy	Ruppertsberger
Clay	Kihuen	Rush
Cleaver	Kildee	Ryan (OH)
Clyburn	Kilmer	Sánchez
Cohen	Kind	Sarbanes
Connolly	Krishnamoorthi	Schakowsky
Conyers	Kuster (NH)	Schneider
Cooper	Langevin	Schrader
Correa	Larsen (WA)	Scott (VA)
Courtney	Larson (CT)	Scott, David
Crist	Lawrence	Serrano
Cuellar	Lawson (FL)	Sewell (AL)
Davis (CA)	Lee	Sherman
Davis, Danny	Levin	Sinema
DeFazio	Lewis (GA)	Slaughter
DeGette	Lipinski	Smith (WA)
Delaney	Loebssack	Soto
DeLauro	Lofgren	Speier
DelBene	Lowenthal	Suozzi
Demings	Lowey	Swallow (CA)
DeSaulnier	Lujan Grisham, M.	Takano
Deutch	Luján, Ben Ray	Thompson (C)
Dingell	Lynch	Thompson (M)
Doggett	Maloney,	Titus
Doyle, Michael F.	Carolyn B. Maloney, Sean	Tonko
Ellison	Matsui	Tsongas
Engel	McCullum	Vargas
Eshoo	McEachin	Veasey
Espaiat	McGovern	Vela
Esty (CT)	McNerney	Velázquez
Evans	Meeks	Visclosky
Foster	Meng	Walz

RECORDED VOTE

A recorded vote was ordered.

The SPEAKER pro tempore. This will be a 5-minute vote.

The vote was taken by electronic device, and there were—ayes 232, noes 187, not voting 14, as follows:

[Roll No. 348]

AYES—232

Abraham Culberson Higgins (LA)

Aderholt Curbelo (FL) Hill  
Allen Davidson Holding

Adams Gallego

Aguilar	Garamendi	Norcross
Barragán	Gohmert	O'Halleran
Bass	Gomez	O'Rourke
Beatty	Gonzalez (TX)	Pallone
Bera	Gottheimer	Panetta
Beyer	Green, Al	Pascarel
Bishop (GA)	Green, Gene	Payne
Blumenauer	Grijalva	Perlmutter
Blunt Rochester	Gutiérrez	Peters
Bonamici	Hanabusa	Peterson
Boyle, Brendan F.	Hastings	Pingree
Brady (PA)	Heck	Pocan
Brown (MD)	Higgins (NY)	Polis
Brownley (CA)	Himes	Price (NC)
Bustos	Hoyer	Quigley
Butterfield	Huffman	Raskin
Castor (FL)	Jackson Lee	Rice (NY)
Capuano	Jayapal	Richmond
Carbajal	Jeffries	Rosen
Cárdenas	Johnson (GA)	Royal-Allard
Carson (IN)	Johnson, E. B.	Ruiz
Cartwright	Kaptur	Ruppersberger
Castro (TX)	Keating	Rush
Chu, Judy	Kelly (IL)	Ryan (OH)
Cicilline	Kennedy	Sánchez
Clark (MA)	Kihuen	Sarbanes
Clarke (NY)	Kildee	Schakowsky
Clay	Kilmer	Schiff
Cleaver	Kind	Schneider
Clyburn	Krishnamoorthi	Schrader
Cohen	Kuster (NH)	Scott (VA)
Connolly	Langevin	Scott, David
Conyers	Larsen (WA)	Serrano
Cooper	Larson (CT)	Sewell (AL)
Correa	Lawrence	Sherman
Courtney	Lawson (FL)	Sinema
Crist	Lee	Sires
Cuellar	Levin	Slaughter
Davis (CA)	Lewis (GA)	Smith (WA)
Davis, Danny	Lipinski	Soto
DeFazio	Loebssack	Speier
DeGette	Lofgren	Suozzi
Delaney	Lowenthal	Swalwell (CA)
DeLauro	Lowey	Takano
DeBene	Lujan Grisham, M.	Thompson (CA)
Demings	Luján, Ben Ray	Thompson (MS)
DeSaulnier	Lynch	Titus
Deutch	Maloney,	Tonko
Dingell	Carolyn B.	Torres
Doggett	Maloney, Sean	Tsongas
Doyle, Michael F.	Matsui	Vargas
Engel	McCollum	Veasey
Eshoo	McEachin	Vela
Espaillat	McGovern	Velázquez
Esty (CT)	McNerney	Viscosky
Evans	Meeks	Wasserman
Foster	Meng	Schultz
Frankel (FL)	Moore	Waters, Maxine
Fudge	Moulton	Watson Coleman
Gabbard	Murphy (FL)	Welch
	Nadler	Wilson (FL)
	Neal	Yarmuth

## NOT VOTING—14

Barletta	Guthrie	Napolitano
Barr	Hensarling	Pelosi
Costa	Johnson, Sam	Scalise
Crowley	Khanna	Shea-Porter
Cummings	Lieu, Ted	

□ 1452

Mr. LOEBSACK changed his vote from “aye” to “no.”

So the resolution was agreed to.

The result of the vote was announced as above recorded.

A motion to reconsider was laid on the table.

---

ANNOUNCEMENT BY COMMITTEE ON RULES REGARDING AMENDMENT PROCESS FOR H.R. 806, OZONE STANDARDS IMPLEMENTATION ACT OF 2017, AND H.R. 2997, 21ST CENTURY AVIATION INNOVATION, REFORM, AND REAUTORIZATION ACT

Mr. SESSIONS. Mr. Speaker, this morning the Rules Committee issued announcements outlining the amendment processes for two measures that will likely be before the Rules Committee next week.

An amendment deadline has been set for Monday, July 17, at 10 a.m., for H.R. 806, the Ozone Standards Implementation Act of 2017; and Monday, July 17, at noon, for H.R. 2997, the 21st Century AIRR Act.

The text of these measures is presently available on the Rules Committee website.

Feel free to contact me or my staff if we may provide any additional information.

---

MEDICAL CONTROLLED SUBSTANCES TRANSPORTATION ACT OF 2017

The SPEAKER pro tempore. Without objection, 5-minute will continue.

There was no objection.

The SPEAKER pro tempore. The unfinished business is the vote on the motion to suspend the rules and pass the bill (H.R. 1492) to amend the Controlled Substances Act to direct the Attorney General to register practitioners to transport controlled substances to States in which the practitioner is not registered under the Act for the purpose of administering the substances (under applicable State law) at locations other than principal places of business or professional practice, on which the yeas and nays were ordered.

The Clerk read the title of the bill.

The SPEAKER pro tempore. The question is on the motion offered by the gentleman from Texas (Mr. BURGESS) that the House suspend the rules and pass the bill.

This is a 5-minute vote.

The vote was taken by electronic device, and there were—yeas 416, nays 2, not voting 15, as follows:

## [Roll No. 349]

## YEAS—416

Abraham	DelBene	Jordan	Palmer	Ruppersberger	Thompson (PA)
Adams	Demings	Joyce (OH)	Panetta	Rush	Thornberry
Aderholt	Denham	Kaptur	Pascrell	Russell	Tiberi
Aguilar	Dent	Katko	Paulsen	Rutherford	Tipton
Allen	DeSantis	Keating	Payne	Ryan (OH)	Titus
Amash	DeSaulnier	Kelly (IL)	Pearce	Sánchez	Tonko
Amodei	DesJarlais	Kelly (MS)	Pelosi	Sanford	Torres
Arrington	Deutch	Kelly (PA)	Perlmutter	Sarbanes	Trott
Babin	Diaz-Balart	Kennedy	Perry	Schakowsky	Tsongas
Bacon	Dingell	Kihuen	Peters	Schiff	Turner
Banks (IN)	Doggett	Kildee	Peterson	Schneider	Upton
Barletta	Donovan	Kilmer	Pingree	Schrader	Valadao
Barragán	Doyle, Michael	Kind	Poliquin	Schweikert	Vargas
	F.	King (IA)	Pittenger	Scott, Austin	Veasey
Bass	Duffy	King (NY)	Pocan	Scott, David	Vela
Beatty	Duncan (SC)	Kinzinger	Poe (TX)	Sensenbrenner	Velázquez
Bera	Duncan (TN)	Knight	Raskin	Serrano	Visclosky
Bergman	Dunn	Krishnamoorthi	Ratcliffe	Sessions	Wagner
Beyer	Ellison	Kuster (NH)	Reichert	Shuster	Walberg
Biggs	Emmer	Kustoff (TN)	Renacci	Simpson	Walz
Bilirakis	Engel	Labrador	Rice (NY)	Sinema	Wasserman
Bishop (GA)	Eshoo	LaMalfa	Rice (SC)	Sires	Schultz
Bishop (MI)	Espallat	Lamborn	Richmond	Slaughter	Waters, Maxine
Bishop (UT)	Estes (KS)	Lance	Roby	Smith (MO)	Watson Coleman
Black	Esty (CT)	Langevin	Roe (TN)	Smith (NE)	Weber (TX)
Blackburn	Evans	Larsen (WA)	Rogers (AL)	Smith (NJ)	Webster (FL)
Blum	Farenthold	Larson (CT)	Rogers (KY)	Smith (TX)	Welch
Blumenauer	Faso	Latta	Rohrabacher	Smith (WA)	Wenstrup
Blunt Rochester	Ferguson	Lawrence	Rokita	Smucker	Westerman
Bonamici	Fitzpatrick	Lawson (FL)	Rooney, Francis	Soto	Williams
Bost	Fleischmann	Lee	Rooney, Thomas	Speier	Wilson (FL)
Boyle, Brendan	Flores	Levin	J.	Stefanik	Wilson (SC)
	F.	Fortenberry	Lewis (GA)	Ros-Lehtinen	Wittman
Brady (PA)	Foster	Lewis (MN)	Rosen	Stivers	Womack
Brady (TX)	Foxx	Lipinski	Roskam	Suozzi	Woodall
Brat	Frankel (FL)	LoBiondo	Ross	Swalwell (CA)	Yarmuth
Bridenstine	Franks (AZ)	LoBrock	Rothfus	Takano	Yoder
Brooks (AL)	Frelinghuysen	Lofgren	Rouzer	Taylor	Yoho
Brooks (IN)	Fudge	Long	Royal-Allard	Tenney	Young (AK)
Brown (MD)	Gabbard	Loudermilk	Royce (CA)	Thompson (CA)	Young (IA)
Brownley (CA)	Gaetz	Love	Ruiz	Thompson (MS)	Zeldin
Buchanan	Gallagher	Lowenthal			
Buck	Gallego	Lowey			
Bucson	Garamendi	Lucas			
Budd	Garrett	Luetkemeyer			
Burgess	Gianforte	Lujan Grisham, M.			
Bustos	Gibbs	Maloney, Sean			
Butterfield	Gomez	Marchant			
Byrne	Gonzalez (TX)	Marino			
Calvert	Goodlatte	Marshall			
Capuano	Gosar	Mast			
Carbajal	Gottheimer	Matsui			
Cárdenas	Gowdy	McCarthy			
Carson (IN)	Granger	McCauley			
Carter (GA)	Graves (GA)	McClintock			
Carter (TX)	Graves (LA)	McCollum			
Cartwright	Graves (MO)	McEachin			
Castor (FL)	Green, Al	McGovern			
Castro (TX)	Green, Gene	McHenry			
Chabot	Griffith	McKinley			
Cheney	Grijalva	McMorris			
Chu, Judy	Grothman	McNerney			
Cicilline	Hanabusa	McSally			
Clark (MA)	Handel	McCarthy			
Clarke (NY)	Harper	McCauley			
Clay	Harris	McClintock			
Cleaver	Hartzler	McCollum			
Clyburn	Hastings	McEachin			
Coffman	Heck	McGovern			
Cohen	Hensarling	McHenry			
Cole	Herrera Beutler	McKinley			
Collins (GA)	Hice, Jody B.	McMorris			
Collins (NY)	Higgins (LA)	McNerney			
Comer	Higgins (NY)	McSally			
Comstock	Hill	McCarthy			
Conaway	Himes	McClintock			
Connolly	Holding	McCollum			
Conyers	Hollingsworth	McEachin			
Cook	Hoyer	McGovern			
Cooper	Hudson	McHenry			
Correa	Huffman	McKinley			
Costello (PA)	Huizenga	McMorris			
Courtney	Hultgren	McNerney			
Cramer	Hunter	McSally			
Crawford	Hurd	McCarthy			
Crist	Issa	McClintock			
Cuellar	Jackson Lee	McCollum			
Culberson	Jayapal	McEachin			
Curbelo (FL)	Jeffries	McGovern			
Davis (CA)	Jenkins (KS)	McHenry			
Davis, Danny	Jenkins (WV)	McKinley			
Davis, Rodney	Johnson (GA)	McMorris			
DeFazio	Johnson (LA)	McNerney			
DeGette	Johnson (OH)	McSally			
Delaney	Johnson, E. B.	McCarthy			
DeLauro	Jones	McClintock			

Palmer	Ruppersberger
Panetta	Rush
Pascrell	Russell
Paulsen	Rutherford
Payne	Ryan (OH)
Pearce	Sánchez
Pelosi	Tonko
Perlmutter	Torres
Perry	Trott
Peters	Tsangas
Pingree	Turner
Poliquin	Upton
Pittenger	Valadao
Pocan	Vargas
Poe (TX)	Velásquez
Raskin	Wagner
Ratcliffe	Walberg
Reichert	Walder
Renacci	Walker
Rice (NY)	Walorski
Rohrabacher	Walters, Mimi
Rokita	Waltrip
Rosney, Francis	Waterson, Maxine
Rosney, Thomas	Watson Coleman
Rouzer	Weber (TX)
Royal-Allard	Webster (FL)
Royce (CA)	Welch
Ruiz	Wenstrup

Rosen	Womack
Roskam	Woodall
Ross	Yarmuth
Rothfus	Yoder
Rouzer	Yoho
Royal-Allard	Young (AK)
Royce (CA)	Young (IA)
Ruiz	Zeldin

## NAYS—2

Barr	Guthrie	Lieu, Ted
Costa	Gutiérrez	Napolitano
Crowley	Johnson, Sam	Reed
Cummings	Khanna	Scalise
Davidson	LaHood	Shea-Porter

□ 1506

So (two-thirds being in the affirmative), the rules were suspended and the bill was passed.

The result of the vote was announced as above recorded.

A motion to reconsider was laid on the table.

## PERSONAL EXPLANATION

Mrs. NAPOLITANO. Mr. Speaker, I was absent during rollcall votes No. 347, No. 348, and No. 349 due to my spouse’s health situation in California. Had I been present, I would have voted “nay” on the Motion on Ordering the Previous Question on the Rule providing for consideration of both H.R. 23 and H.R. 2810. I would have also voted “nay” on H. Res. 431—Rule providing for consideration of both H.R. 23—Gaining Responsibility on Water Act of 2017 and H.R. 2810—National Defense Authorization Act for Fiscal Year 2018. I would have also voted “yea” on H.R. 1492—Medical Controlled Substances Transportation Act of 2017.

## PERSONAL EXPLANATION

Mr. CROWLEY. Mr. Speaker, on July 12, 2017, due to a family commitment I was absent for recorded votes No. 347, No. 348, and No. 349. Had I been present, on rollcall No. 347, I would have voted “no”; on rollcall No. 348, I would have voted “no”; and on rollcall No. 349, I would have voted “yes.”